Category:

A Curia apoia o ensaio clínico de fase 1 da nova vacina de RNA de última geração da Replicate Bioscience

O fornecimento de um fármaco fabricado segundo as normas de BPFa apoia o primeiro estudo clínico em seres humanos do novo RNA autorreplicante (srRNA) RBI-4000 ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato, anunciou hoje que sua parceira, Replicate Bioscience, recebeu autorização IND […]

September 13, 2023

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA) ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with […]

September 13, 2023

Deriv Group to launch Deriv Prime at IFX EXPO Cyprus 2023

Deriv Prime – Liquidity solution provider LIMASSOL, Cyprus, Sept. 13, 2023 (GLOBE NEWSWIRE) — Deriv Group has announced that it will launch its institutional arm, Deriv Prime, at the upcoming IFX Expo in Limassol, Cyprus, from the 19th to the 21st of September 2023. The venture aims to reshape the landscape of liquidity access and trading […]

September 13, 2023

Deriv Group lancera Deriv Prime lors du IFX EXPO Cyprus 2023

Deriv Prime – Les solutions de liquidité LIMASSOL, Chypre, 13 sept. 2023 (GLOBE NEWSWIRE) — Deriv Group a annoncé le lancement prochain de Deriv Prime, sa branche institutionnelle, lors de l’IFX Expo qui se déroulera du 19 au 21 septembre 2023 à Limassol (Chypre). L’entreprise entend redéfinir le cadre d’accès aux liquidités et la dynamique […]

September 13, 2023

EMAIL NEWSLETTER

Subscribe to receive inspiration, ideas, and news in your inbox

  • Trending

1.

2.

3.

4.

5.

  • Recent
  • Advertisement